Endo International to acquire Par Pharmaceutical for $8.05B, PENTAX continues to work with FDA on scope infections & more – 7 GI/endoscopy company key notes

Here are seven recent news updates on gastroenterology and endoscopy companies.

Ernest Mario, director with Boston Scientific, sold 50,000 shares of company stock for a total transaction value of $904,500, according to a Dakota Financial News report.

Biotechnology company ColonaryConcepts enrolled its first patient in a phase 2 clinical trial of colon preparation. 

Commonwealth Laboratories, based in Salem, Mass., launched IBSchek, a blood test designed to detect irritable bowel syndrome.

Endo International will acquire Par Pharmaceutical for $8.05 billion in cash and stock, according to a report by The New York Times. The deal will result in one of the five largest generic drug companies in the country.

Mauna Kea Technologies' Cellvizio technology received a CE mark for use in minimally invasive laparoscopic surgical indications.

Mederi Therapeutics announced two milestones for its Stretta Therapy. Stretta has now been used for the treatment of GERD in 18,000 cases. The therapy has also received new regulatory approval in the Australia, Argentina, India, Mexico, South Africa and South Korea markets.

PENTAX Medical reiterated its commitment to working with the FDA to address infection risk associated with duodenoscopes. 

If you have a question, issue or note to suggest on a GI/endoscopy company please contact Carrie Pallardy at cpallardy@beckershealthcare.com.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Articles We Think You'll Like

 

Featured Whitepapers

Featured Webinars